A New Treatment for Local Adiposity with Ascorbic Acid and Ascorbyl-Palmitate Solution: Clinical and Histological Study

Increased caloric intake and reduction of energy demand can be cause excessive body weight and excessive localized fat. Excessive localized fat and body weight may weaken health, acknowledging different multiple factors such as physical, psychological, and genetic causes. The increasing demand for methods of body fat reduction is maybe driven by the fact that 13% of the world’s adult population (15% of women and 11% of men) were obese in 2016 according to the WHO World Health Statistics Report 2020 [1]

For classifying overweight in adults, we use weight-for-height that is commonly known as BMI. It is calculated by weight in kilograms divided by the square of height in meters (kg/m²). The BMI, however, is insufficient for evaluating risk factors and does not take fat distribution into account, but it is associated with health impairment [2]. For this reason, the waist-to-hip ratio (WHR), waist circumference divided by the hip circumference, was proposed as this index takes into account the differences in body structure, fat distribution and has more sensitivity in the prediction of several diseases that can cause mortalities [3, 4]. Furthermore, it is increasingly evident that excess abdominal fat is closely associated with the development of metabolic disturbances [5‐7] while accumulation of fat in the lower body is associated with a protective glucose and lipid profile after adjustment for total body fat mass [8, 9].

On the contrary, localized adiposity (AL) is the accumulation of subcutaneous adipose tissue, placed in definite anatomic areas, building up an alteration of the body silhouette. Usually, undesirable fat is situated in the abdomen, flanks, and thighs back, arms, and chest. Excessive localized fat is also an aesthetical problem, physical appearance has great value, and many patients who suffer from excessive localized fat feel weakened with a big impact on relationships with friends or loved ones, the social environment, lowering self-esteem, and affects personal and professional life in general.

Body fat distribution is influenced by genetic makeup [10], epigenetic mechanisms [11, 12], sex hormones, use of glucocorticoids [13]. The reduction in the calories consumed, a balanced diet and lifestyle changes must be recommended for weight loss and the reduction in risk factors.

Liposuction or injection lipolysis techniques have been proposed for removing the excess subcutaneous fat for improving the aesthetical appearance. Liposuction is a gold-standard procedure used in clinical practice [14]; however, it is an expensive and is a surgical procedure which often needs general anesthesia. For these reasons, most studies propose particularly non-invasive techniques for the reduction of subcutaneous fat layers such as injections of lipolysis [15], cryolipolysis [16], radiofrequency ablation [17], and HIFU (high-intensity focused ultrasound) [18]. Today, more patients demand noninvasive techniques for reducing local fat, representing now the fastest growing area of aesthetic medicine. The first technique proposed was infra-adipose injections of phosphatidylcholine and deoxycholic acid which were available for efficacious chemical lipolysis [15]. Vitamin C (ascorbic acid) was used mixed with Klein solution because it increased lipolysis and could improve skin retraction where liposuction did not achieve good results [19]. Many clinical studies report that BMI and fat distribution plasma are inversely related to plasma concentration of AA [20, 21].

In this paper, we aimed to illustrate the efficacy of sodium ascorbate for the treatment of local adiposity. The aim of the present clinical and histological study is to determine the efficacy of an injectable solution containing sodium salt of ascorbic acid 0.24% and surfactant agent at 0.020% ascorbyl-palmitate (SAP) for treating local adiposity.

The study was based in a private multi-specialty medical clinical practice in Montesilvano (Italy), in full accordance with ethical principles, including the World Medical Association Declaration of Helsinki (https://​www.​wma.​net/​wp-content/​uploads/​2018/​07/​DoH-Oct2008.​pdf) and the additional requirements of Italian law. The sample included 80 healthy adult female patients, suffering from local adiposity in the abdominal region. The patients were treated between January 2008 and December 2019. The selected patients were between 25 and 65 years of age, Body Mass Index (BMI) between 23 and 26 with normal weight or slightly overweight without history of adverse health conditions. Each patient signed informed consent on the adopted procedure, and all of the patients knew which pathology the treatment was aimed at. Inclusion criteria for the study included patients with excess adiposity in the abdominal region and who wanted a nonsurgical option for reduction of the same. Exclusion criteria included pregnancy and lactation, menstrual cycle, local infections or skin problems, and anticoagulant medications.

The adipocytolytic agent used was a sodium salt of ascorbic acid 0.24% and surfactant agent at 0.020% ascorbyl-palmitate (SAP) an isotonic solution for sodium chloride in phosphate buffer (Skin-Fat, Ital Farmacia, Rome, Italy). The SAP was introduced via a 5 mL syringe with a 24G needle and a length of 16 cm, very similar to the needles used for spinal anesthesia.

Maintaining the patient seated, infiltration was performed after first disinfecting the area to be treated.

The index finger and thumb of the free hand was used to lift the skin and to exert light pressure on the abdominal area while the needle entered directly on the point of maximum projection of the fat pad to be treated, perpendicular to the skin. After piercing the skin with the needle and passing through the dermis, there was an immediate sensation of loss of resistance to the advancement of the needle. After entering for 2–3 cm, it orientated parallel to the skin plane when the depth of the injection was 3–4 cm (Fig. 1a). This was the signal of having reached the fat under the skin and the right plane, continuing until all 16 cm of the needle entered and the pharmacologically active solution was released into the adipose tissue. During this phase, the needle was neither visible nor palpable on the skin surface, each infiltration of 0.5 mL was a retrograde and fanning insertion (Fig. 1b). The product should not be diluted and the infiltration speed must be moderate. An amount of 0.5 mL of SAP solution was released and while the needle was being removed, the remaining solution (4.5 mL) was gradually released. This procedure was repeated 4 times and a total 20 mL SAP solution was infiltrated into the abdominal region. During all 6 section, a total 120 mL of solution was patient get. Direct infiltration of pharmacologically active solutions into the adipose tissue, with a moderate infiltration speed, is a quick and painless procedure (does not require any anesthesia). While performing the least number of entry points into the skin, it is important to provide a homogeneous coverage of the anatomical region to be treated.

Immediately after the treatment, the use of an icepack was compulsory for 15′ for reducing edema and avoiding pain in the post-treatment phase. The patients underwent a cycle of 6 sessions, with biweekly treatments, without the addition of any active ingredient.

Aesthetic outcomes were evaluated by the authors using preoperative and postoperative photographic documentation and thorough clinical examination and metric documentation with waist-to-hip Ratio (WHR) index. Waist and hip circumferences were measured with the subject in a standing position using a flexible metric measuring tape to the nearest 0.5 cm.

Localized swellings were reported in the abdominal region, no patients reported erythema following the injections, only six patients reported formation of subcutaneous nodules resolved over 7–14 days. All patients treated showed good results with good satisfaction of the circumferential reductions (Figs. 2a, b, 3a–c). Before treatment: Waist [cm] 78.8 ± 10.6 and hip 93.6 ± 9.0 with WHR 0.84 ± 0.07. After treatment: Waist [cm] 70.8 ± 9.6 and hip 92.6 ± 8.0 with WHR 0.76 ± 0.06 (Figs. 2, 3).

The average circumferential reduction after treatment was 8.1(± 9.6) cm while the WHR was decreased to 0.08 (Table 1).

The results of the present study indicate that the adipocytolytic agent with SAP is associated with a lipoclase effect and reduction in vital adipocytes without increase in fibrosis. The clinical results showed a statistical signification reduction in waist circumferences and reduction in WHR index. The average circumferential reduction after treatment was 8.1 ± 0.6 cm, while the WHR was decreased to 0.08 ± 0.6.

Localized adiposity (AL) is accumulations of subcutaneous adipose tissues, placed in definite anatomic areas, building up an alteration of the body silhouette. They are characterized by an increase in volume (hypertrophy) and in the number of the adipocytes (hyperplasia), without histological stromal-parenchymal changes of the cellular structure and without modifications of the hypodermal and dermal microcirculation.

In the AL, dermis and epidermis maintain intact their characteristics, without undergoing alterations. AL is a local increase in healthy adipose tissue, without significant clinical signs of disease: there is no edema, no pain, no skin alteration, differently to what occurs with cellulite.

Even histologically, AL do not show pathological changes: adipose tissue is alternatingly hypertrophic and hyperplastic, without anisopoikilocytosis, and is normally vascularized and made up of very large adipocytes, which are greater than 100 μm in diameter and globular, surrounded by a network of reticular fibers, laying one on another with low interposition of intercellular substance.

The reduction in localized fat, intralipotherapy, is used with success in aesthetical medicine, the purpose is creating adipocytolytes with substances by direct injection into fatty tissue with a long needle. This technique, used frequently for over 15 years, uses phosphatidylcholine mixed with sodium deoxycholate as a surfactant agent, a new study while several studies have been carried out where the adipocytolytic agent is sodium deoxycholate and not phosphatidylcholine [22].

In the present study, we chose the adipocytolytic sodium ascorbate mixed with ascorbyl-palmitate as a surfactant agent because the lower vitamin C plasma level is significantly associated with obesity [23]. The increase in levels of vitamin C plasma through supplementation has direct effects on behavioral activity and on adipocyte lipolysis in rats model [24] and its intake promotes weight loss in obese men and women [25, 26]. Animal studies show that diet supplementation of vitamin C reduces by 46% mesenteric adipose tissue mass, adipocyte size and can be used in preventing or treating visceral obesity and glucose intolerance [27]. The ascorbic acid inhibits adipocyte differentiation by inhibiting adenylate cyclase, acting as a global regulator of intracellular cyclic adenosine monophosphate (cAMP) levels and sodium-dependent vitamin C transporter 2 (SVCT2), and is probably involved in these differentiation processes [28] with suppression of peroxisome proliferator-activated receptor α and reduce visceral obesity [29]. Ascorbic acid was also used with intravenous infusion against vascular responses to exercise in obese humans [30] or for reducing allergic response of the skin after local treatment [31], so its administration is safe and adverse reaction free. The physiology of adipocyte is not fully known. High dosage of vitamin C induces adipocyte cell death with autophagy through increases in the levels of intracellular Ca2 + and reactive oxygen species (ROS) and decreases the production of intracellular ATP [32, 33] with the same mechanism induces cancerous cell death [32, 34]. Ascorbyl Palmitate was associated because it presents a lipophilic component with a hexadecanoic chain that facilitates the interaction between the lipid phase and the aqueous phase, increasing the dispersibility and the emulsifying capability [35]. Vitamin C, modulates the release of catabolic inflammatory cytokines, and can regulate the inflammatory process and stimulate the tissue repair [36, 37]. The effect of autophagy may be linked to apoptosis, but not to necrosis or cytoprotective processes. Tissue necrosis and apoptosis are the two major mechanisms of cell death. Apoptosis is a method of programmed cell death to remove cells damaged by noxious agents or disease [38, 39].

Our outcome suggests that SAP increased adipocyte apoptosis. Intra-dipose injection of SAP produces an extensive fat contraction resulting in apoptosis of adipocyte, no adverse events were observed to skin and surrounding tissue. The subjects were normal weight or slightly overweight without complications of any diagnosis of degenerative diseases and lifestyle habits that would have favored aging such as: smoking, alcohol abuse, etc. The interesting study demonstrates that adipocyte apoptosis is an effective and irreversible method for removing subcutaneous fat, while weight loss through diet reduction decreased the volume of adipocytes without decreases in actual fat cell numbers [40, 41]. Therefore, a decrease in the number of adipocytes can be a rational approach to relieve the undesired expansion of adipose tissue. This is an important aspect because the adipocytes have a mean lifespan of 10 years with only 10% of all adipocytes undergo a yearly renewal process [41]. The limitations of the present study are that all subjects were females, and we did not investigate the difference between the two sexes and we have not randomized the patients.

The treatment with SAP is painless, except for the possible sensation of pain at the site of injection, although the treated patients did not report any sensation of pain. The treatment, once carried out by maintaining sterility requirements and medical common sense, is absolutely safe, and it is effective for reducing undesirable subcutaneous abdominal fat deposits in subjects with normal weight or slightly overweight without disease complications.